<DOC>
	<DOCNO>NCT01468571</DOCNO>
	<brief_summary>The purpose study determine effect spironolactone collagen marker large number patient pulmonary hypertension . In addition , safety tolerability spironolactone , aldosterone receptor antagonist , patient pulmonary arterial hypertension , determine .</brief_summary>
	<brief_title>Effects Spironolactone Collagen Metabolism Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Pulmonary arterial hypertension ( PAH ) orphan disease characterize pulmonary artery hypertrophy , result vascular remodel involved vessel , often lead right heart failure . Accumulating evidence vascular biology , animal model , therapeutic drug trial suggest significant contribution neurohormonal milieu disease process , morbidity , mortality . The renin-angiotensin-aldosterone system ( RAAS ) important neurohormonal pathway induces collagen synthesis myocardium systemic vasculature . There paucity data regard contribution RAAS pathogenesis PAH effect aldosterone blockade amelioration PAH . Thus , overall goal proposal investigate contribution RAAS pathogenesis PAH , explore effect aldosterone blocker , spironolactone , PAH .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Age 18 year old Body weight &gt; 40 kg PAH Diagnostic Group I Stable subject change PAH specific therapy within last 4 week No change dose background therapy ( digoxin , diuretic ) within last 2 week exclude anticoagulation Unable give inform consent Hemodynamically unstable subject Pregnant breast feeding Have significant renal insufficiency ( serum creatinine &gt; 2.5 mg per deciliter require hemodialysis ) Have significant liver dysfunction ( AST ALT three time upper limit normal ) Currently aldosterone receptor blocker ( spironolactone eplerenone ) ACE inhibitor PH due leave heart disease Unable unwilling comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Potassium Sparing Diuretics</keyword>
	<keyword>Right-sided heart failure</keyword>
	<keyword>Edema</keyword>
</DOC>